Cost- Minimization Analysis of the Direct Costs of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Ckd-nd Patients.

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKDMBD). Kidney International 2009; 76(suppl 113):S1-S130 2. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolo P, Malmusi G, Santoro A (2011) Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 6 (4):883-891 3. Russo D, Corrao S, Battaglia Y, Andreucci M, Caiazza A, Carlomagno A, Lamberti M, Pezone N, Pota A, Russo L, Sacco M, Scognamiglio B (2011) Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 80 (1):112-118 4. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 (1):31-38 5. Smith DH, Johnson ES, Thorp ML, Petrik A, Yang X, Blough DK (2010) Outcomes predicted by phosphorous in chronic kidney disease: a retrospective CKD-inception cohort study. Nephrol Dial Transplant 25 (1):166-174 6. Tonelli, M., et al., Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation, (2005). 112(17): p. 2627-33 7. Block, G.A., et al., Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology : JASN, 2004. 15(8): p. 2208-18 8. Wilson RJ, Keith M, Copley JB (2013) Analysis of the cost-effectiveness of switching from sevelamer carbonate to lanthanum carbonate monotherapy in the European Union. (abstract # MP 549) Nephrology Dialysis Transplantation vol.28 (1): i460–i471, 2013 9. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J,Duggal A, Kalra PA (2008) Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3 (4):1125-1130 10. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W (2009a) Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4: A Randomized Trial. Clin J Am Soc Nephrol 4: 178–185. 11. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R (2009) Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clinical Nephrology 72 (4):252-258 12. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ (2007) A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology 68 (6):386-391 13. Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N (2009) A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 24 (12):3794-3799. 14. Bulgarian National Statistical Institute internet site – Census database (2011) http://www.nsi.bg/census2011/index.php 15. Krivoshiev S, Borisova AM, Shinkov A, Svinarov D, Vlachov J, Koteva A, Dakovska L, Mihaylov G, Popov A (2014) CHRONIC KIDNEY DISEASES IN NATIONAL REPRESENTATIVE SURVEY FOR ENDOCRINE AND KIDNEY DISEASES IN BULGARIA, Nephrol. Dial. Transplant. 29 (suppl 3): iii124– iii139 CONCLUSION OBJECTIVES